|
Neuroblastoma
|
|
0.850 |
GeneticVariation
|
BEFREE |
Our findings revealed that rs110419 and rs2168101 polymorphisms were significantly associated with a decreased risk of NB in all genetic models.
|
31830377 |
2020 |
|
Neuroblastoma
|
|
0.850 |
GeneticVariation
|
BEFREE |
<b>Results:</b> Significant associations with neuroblastoma risk were found for four (rs110419, rs4758051, rs10840002, and rs2168101) out of the five polymorphisms.
|
30406033 |
2018 |
|
Neuroblastoma
|
|
0.850 |
GeneticVariation
|
BEFREE |
We also confirmed that rs6939340 A>G (G versus A: OR=1.30, 95% CI=1.13-1.50) and rs110419 G>A (A versus G: OR=1.37, 95% CI=1.19-1.58) were associated with increased neur</span>oblastoma risk for all subjects.
|
29024823 |
2017 |
|
Neuroblastoma
|
|
0.850 |
GeneticVariation
|
BEFREE |
We found that the rs110419 A > G polymorphism was associated with a significantly decreased neuroblastoma</span> risk (AG vs. AA: adjusted OR = 0.65, 95% CI = 0.47-0.91; GG vs. AA: adjusted OR = 0.58, 95% CI = 0.36-0.91; AG/GG vs. AA: adjusted OR = 0.63, 95% CI = 0.46-0.86), and the protective effect was more predominant in children of age > 18 months, males, subgroups with tumor in adrenal gland and mediastinum, and patients in clinical stages III/IV.
|
27009839 |
2016 |
|
Neuroblastoma
|
|
0.850 |
GeneticVariation
|
BEFREE |
A major haplotype, ATC, containing rs204926, rs110420, and rs110419, conferred a significant increase in risk for NB (OR = 1.82, 95% CI: 1.41-2.36, adjusted P < 0.001).
|
26030754 |
2015 |
|
Neuroblastoma
|
|
0.850 |
GeneticVariation
|
GWASDB |
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.
|
22941191 |
2012 |
|
Neuroblastoma
|
|
0.850 |
GeneticVariation
|
GWASCAT |
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma.
|
22941191 |
2012 |
|
Neuroblastoma
|
|
0.850 |
GeneticVariation
|
GWASCAT |
Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
|
21124317 |
2011 |
|
Neuroblastoma
|
|
0.850 |
GeneticVariation
|
GWASDB |
Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
|
21124317 |
2011 |
|
Body Height
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Evaluation and application of summary statistic imputation to discover new height-associated loci.
|
29782485 |
2018 |
|
Diastolic blood pressure
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension.
|
27618447 |
2016 |
|
Central neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Our findings revealed that rs110419 and rs2168101 polymorphisms were significantly associated with a decreased risk of NB in all genetic models.
|
31830377 |
2020 |
|
Childhood Neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
Our findings revealed that rs110419 and rs2168101 polymorphisms were significantly associated with a decreased risk of NB in all genetic models.
|
31830377 |
2020 |
|
Childhood Neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
<b>Results:</b> Significant associations with neuroblastoma risk were found for four (rs110419, rs4758051, rs10840002, and rs2168101) out of the five polymorphisms.
|
30406033 |
2018 |
|
Central neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
<b>Results:</b> Significant associations with neuroblastoma risk were found for four (rs110419, rs4758051, rs10840002, and rs2168101) out of the five polymorphisms.
|
30406033 |
2018 |
|
Childhood Neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
We also confirmed that rs6939340 A>G (G versus A: OR=1.30, 95% CI=1.13-1.50) and rs110419 G>A (A versus G: OR=1.37, 95% CI=1.19-1.58) were associated with increased neur</span>oblastoma risk for all subjects.
|
29024823 |
2017 |
|
Central neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
We also confirmed that rs6939340 A>G (G versus A: OR=1.30, 95% CI=1.13-1.50) and rs110419 G>A (A versus G: OR=1.37, 95% CI=1.19-1.58) were associated with increased neur</span>oblastoma risk for all subjects.
|
29024823 |
2017 |
|
Central neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
We found that the rs110419 A > G polymorphism was associated with a significantly decreased neuroblastoma</span> risk (AG vs. AA: adjusted OR = 0.65, 95% CI = 0.47-0.91; GG vs. AA: adjusted OR = 0.58, 95% CI = 0.36-0.91; AG/GG vs. AA: adjusted OR = 0.63, 95% CI = 0.46-0.86), and the protective effect was more predominant in children of age > 18 months, males, subgroups with tumor in adrenal gland and mediastinum, and patients in clinical stages III/IV.
|
27009839 |
2016 |
|
Childhood Neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
We found that the rs110419 A > G polymorphism was associated with a significantly decreased neuroblastoma</span> risk (AG vs. AA: adjusted OR = 0.65, 95% CI = 0.47-0.91; GG vs. AA: adjusted OR = 0.58, 95% CI = 0.36-0.91; AG/GG vs. AA: adjusted OR = 0.63, 95% CI = 0.46-0.86), and the protective effect was more predominant in children of age > 18 months, males, subgroups with tumor in adrenal gland and mediastinum, and patients in clinical stages III/IV.
|
27009839 |
2016 |
|
Childhood Neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
A major haplotype, ATC, containing rs204926, rs110420, and rs110419, conferred a significant increase in risk for NB (OR = 1.82, 95% CI: 1.41-2.36, adjusted P < 0.001).
|
26030754 |
2015 |
|
Central neuroblastoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
A major haplotype, ATC, containing rs204926, rs110420, and rs110419, conferred a significant increase in risk for NB (OR = 1.82, 95% CI: 1.41-2.36, adjusted P < 0.001).
|
26030754 |
2015 |
|
Nephroblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Only rs110419 AG was found to be protective against Wilms' tumor (adjusted OR = 0.62, 95% CI = 0.41-0.94, <i>P</i> = 0.024) when compared to rs110419 AA.
|
28881592 |
2017 |
|
Childhood Kidney Wilms Tumor
|
|
0.010 |
GeneticVariation
|
BEFREE |
Only rs110419 AG was found to be protective against Wilms' tumor (adjusted OR = 0.62, 95% CI = 0.41-0.94, <i>P</i> = 0.024) when compared to rs110419 AA.
|
28881592 |
2017 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that the rs110419 A > G polymorphism was associated with a significantly decreased neuroblastoma risk (AG vs. AA: adjusted OR = 0.65, 95% CI = 0.47-0.91; GG vs. AA: adjusted OR = 0.58, 95% CI = 0.36-0.91; AG/GG vs. AA: adjusted OR = 0.63, 95% CI = 0.46-0.86), and the protective effect was more predominant in children of age > 18 months, males, subgroups with tumor in adrenal gland and mediastinum, and patients in clinical stages III/IV.
|
27009839 |
2016 |